ArticleRedox biology2026
Mitochondrial OXPHOS integrates immunometabolic cascade for bone regeneration via coupled ATP production and ROS homeostasis.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoinductive calcium phosphate ceramics (CaPs) hold great promise for bone repair, yet the metabolic principles governing their efficacy are poorly defined. Here, we identify mitochondrial oxidative phosphorylation (OXPHOS) as an early and indispensable pathway activated specifically by an osteoinductive tricalcium phosphate (TCPS) in material-induced bone formation. Our findings demonstrate that OXPHOS critically governs the M2 macrophage-osteoclast axis for bone formation by regulating both cellular energy supply and reactive oxygen species (ROS) homeostasis. Disrupting either function-by inhibiting OXPHOS (reducing ATP production) or by disrupting ROS balance (including ROS scavenging or accumulation)-uncouples this metabolic-immunological cascade and abrogates bone formation. Our work establishes mitochondrial OXPHOS as a central metabolic hub that integrates bioenergetics with ROS balance to orchestrate material-induced bone formation via M2 macrophage polarization-osteoclastogenesis axis. Consequently, these insights provide a rational basis for therapeutic modulation of the immunometabolic cascade in bone regeneration, via strategies designed to co-activate OXPHOS and fine-tune ROS dynamics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.